Paxlovid in Uremic Patients with COVID-19

Phase 1, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard of Care with Paxlovid + SOC (2 arms). Primary endpoints: time of negative conversion of SARS-CoV-2 nucleic acid at 60 days and Proportion of ICU transfer or disease progression to severe or critical illness at 60 days. Status: unknown.